Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Document › Details

CellCura ASA. (1/17/13). "Press Release: CellCura ASA. Entering Asia with First Sale to World Class IVF Institution in Beijing, People’s Republic of China".

Region Region Beijing (Peking)
  Country China
Organisations Organisation CellCura ASA
  Organisation 2 Guangzhou Haoxin Instrument Co., Ltd.
Products Product ART Lab Solution (CellCura)
  Product 2 in vitro fertilisation (IVF)
Index term Index term Guangzhou Haoxin Instrument–CellCura: in viro fertilization technology, 201308 distribution existent in China by Haoxin
Person Person Kvam, Tore (CellCura 201212– acting CEO before CFO)
     


CellCura steps into Asia with the first sale of its ART Lab solution to Peking University Third Hospital IVF Center, People's Republic of China.

With 10 000 cycles per year, Peking University Third Hospital is one of the largest fertility clinics in Asia and is a leader in reproductive technologies in People's Republic of China. The CellCura ART Lab Solution will be immediately operational for routine treatment in the clinic, which is looking to expand its treatment capacity in the next few years, cutting down on ever increasing waiting lists in the region.

This first Chinese contract has been developed in partnership with our distributor Guangzhou Haoxin Instrument Co Ltd and their subsidiary Hong Kong Long Sense Development Ltd.

CellCura's product entry into the Chinese market endorses the concept of the ART Lab solution as fertility clinics worldwide demand better control of the ART procedures to make better treatment decisions and improve success rates for their growing number of patients. Leading Chinese clinics are setting themselves challenging standards for ART treatment and success. Traditional equipment and laboratory set-ups just cannot deliver the results, whilst coping with the numerically large numbers of patients demanding high quality ART treatment.

"This integrated process management for both ART professional and patient is a first for Chinese ART clinics. CellCura's ART Lab solution will help strengthen the patient couple and infertility doctor relationship, so critical to successful treatment in China. Having our system placed in such a prestigious clinic, with a volume 5 times larger than a large European fertility clinic, where it will also be used to train personnel from newly established fertility clinics means that the CellCura ART Lab solutions will set the standard for ART treatments in future generations of clinics in People's Republic of China" says Lesley Hutchins, CEO CellCura Inc.

"Over the last 10 months, we have signed contracts with a number of highly respected clinics in Europe, USA, Saudi Arabia and now finally one in the growing Far East market. Although unit sales still are in an early phase, CellCura is becoming a global provider of state of the art technology, products and solutions within the ART industry" says Tore Kvam, CEO, CellCura ASA.

Oslo, 17. January 2013

CellCura ASA
Tore Kvam
Chief Executive Officer
Phone: +47 959 34 199


CellCura ASA is dedicated to the development and sales of cell technologies for use in assisted reproductive technology (ART) and stem cell research worldwide, representing improved safety and efficiency compared to traditional technology. CellCura ASA is listed on the Oslo Axess market at the Oslo Stock Exchange (ticker: CELL). www.cellcura.com

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for CellCura ASA


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top